Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.

about

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.

P2860

Q52577419-0DFDF822-7F71-49F2-A17E-359E6A7E1A5D Q54118354-F402C565-41E3-423F-A0E9-716A0C455BA8

P2860

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.

Item

http://www.wikidata.org/entity/Q38792519

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Challenges in the treatment of ...... cancer with brain metastases.

@en

type

Item

label

Challenges in the treatment of ...... cancer with brain metastases.

@en

prefLabel

Challenges in the treatment of ...... cancer with brain metastases.

@en

P1476

Challenges in the treatment of ...... cancer with brain metastases.

@en

P2093

Joyce O'Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Minetta C Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.

Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT).

Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer.

Tissue concentration of systemically administered antineoplastic agents in human brain tumors.

P2888

s10555-016-9619-z

P304

323-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-016-9619-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Javier Cortes

P577

2016-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036926586

http://www.w3.org/2001/XMLSchema#string

P698

27023712

http://www.w3.org/2001/XMLSchema#string

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.

about

P2860

P2860

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698